Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X

[1]  C C Bailey,et al.  Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials * , 1995, British journal of haematology.

[2]  G. Rivera.  Advances in therapy for childhood non-B-lymphoblastic leukaemia. , 1994, Bailliere's clinical haematology.

[3]  G. Reaman,et al.  Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Hancock,et al.  Treatment of acute lymphoblastic leukemia : 30 years' experience at St. Jude Children's Research Hospital , 1993 .

[5]  H. Sather,et al.  Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Richards,et al.  Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALLX , 1992, The Lancet.

[7]  M. L. Le Beau,et al.  Impact of chromosomal translocations on prognosis in childhood acute lymphoblastic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Gelber,et al.  Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Peto,et al.  Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood) , 1991, British journal of haematology.

[10]  D Cox,et al.  The contribution of statistical methods to cancer research , 1991 .

[11]  J. Lilleyman,et al.  Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. , 1991, Archives of disease in childhood.

[12]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[13]  J. Shuster,et al.  A pilot study of intermediate‐dose methotrexate and cytosine arabinoside, “Spread‐out” or “Up‐front,” in continuation therapy for childhood non‐T, non‐B acute lymphoblastic leukemia a pediatric oncology group study , 1991 .

[14]  F. Behm,et al.  Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.

[15]  J. Lilleyman,et al.  Testicular irradiation in childhood lymphoblastic leukaemia , 1990 .

[16]  H. Sather,et al.  Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Shuster,et al.  Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Behm,et al.  Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.

[19]  C. R. Pinkerton,et al.  Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study). , 1987, Archives of disease in childhood.

[20]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[21]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[22]  H. Sather,et al.  Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Denis R. Miller,et al.  Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG‐141: A report from childrens cancer study group , 1983, Cancer.

[24]  L. Freedman,et al.  Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.

[25]  W. Looney,et al.  Solid Tumour Models for the Assessment of Different Treatment Modalities: VII: Single vs Fractionated Doses of 5-Fluorouracil on Two Solid Tumours and Their Hosts , 1978, British Journal of Cancer.

[26]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[27]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[28]  G. Henze,et al.  Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.

[29]  Rivera Gk,et al.  Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification, CNS leukemia, and prognostic factors , 1987 .

[30]  M. Schrappe,et al.  Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. , 1987, Haematology and blood transfusion.

[31]  Walker,et al.  Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. , 1986, Blood.